p. 272−278
2345-3656
Vol.14/No.4
p. 279−283
2345-3656
Vol.14/No.4
p. 284−289
2345-3656
Vol.14/No.4
p. 290−298
2345-3656
Vol.14/No.4
0.005). Conclusion: FGFR1 over-expression and amplification may not be related to clinicopathological parameters, namely age, stage, and grade of the cancer not to mention TNBC survival. Using FGFR1 as a prognostic factor in TNBCs requires further study.]]>
p. 299−304
2345-3656
Vol.14/No.4
p. 305−312
2345-3656
Vol.14/No.4
p. 313−316
2345-3656
Vol.14/No.4
p. 317−321
2345-3656
Vol.14/No.4
0.05). Conclusion: We observed that HER2/neu is expressed in one-third of high-grade ECs. This ancillary test is supportive in follow-up of patients with high-grade ECs.]]>
p. 322−328
2345-3656
Vol.14/No.4
p. 329−337
2345-3656
Vol.14/No.4
p. 338−341
2345-3656
Vol.14/No.4
p. 342−346
2345-3656
Vol.14/No.4